Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 981 to 990 of 1514 total matches.

Dupilumab (Dupixent) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
was effective irrespective of baseline blood 7 The Medical Letter ® Vol. 61 (1563) January 14, 2019 ...
The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):6-8 |  Show IntroductionHide Introduction

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
of this material is strictly prohibited. For further information call: 800-211-2769 27 The Medical Letter ® Vol ...
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-8 |  Show IntroductionHide Introduction

Prucalopride (Motegrity) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
The Medical Letter ® Vol. 61 (1573) June 3, 2019 ADVERSE EFFECTS — In the 6 placebo-controlled clinical ...
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):86-8 |  Show IntroductionHide Introduction

Colorectal Cancer Screening

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
or 2 first-degree relatives of any age. 98 The Medical Letter ® Vol. 61 (1575) July 1, 2019 than ...
Most colorectal cancers arise from localized adenomatous polyps in a process that may take 10 years or more. Early detection and removal of a precancerous colonic lesion (polyp) can prevent cancer from developing.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):97-9 |  Show IntroductionHide Introduction

Benzhydrocodone/Acetaminophen (Apadaz) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
administration of 2 crushed tablets, hydrocodone 111 The Medical Letter ® Vol. 61 (1576) July 15, 2019 ...
The FDA has approved Apadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate. Benzhydrocodone is a prodrug of hydrocodone. Fixed-dose combinations of short-acting hydrocodone and acetaminophen or ibuprofen have been available for years and are the most abused opioid products in the US. Apadaz was developed under the presumption that inclusion of the inactive prodrug would reduce the potential for...
Med Lett Drugs Ther. 2019 Jul 15;61(1576):110-2 |  Show IntroductionHide Introduction

Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
, have been reported in clinical trials. 184 The Medical Letter ® Vol. 61 (1585) November 18, 2019 ...
The FDA has approved upadacitinib (Rinvoq – Abbvie), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or cannot tolerate methotrexate (Trexall, and others). Upadacitinib is the third JAK inhibitor to be approved in the US for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) and baricitinib (Olumiant) were approved earlier.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):183-5 |  Show IntroductionHide Introduction

Minocycline Foam (Amzeeq) for Acne

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
kg: 60 mg; 55-84 kg: 100 mg; 85-136 kg: 150 mg). 69 The Medical Letter ® Vol. 62 (1597) May 4, 2020 ...
The FDA has approved a 4% aerosol foam formulation of minocycline (Amzeeq – Foamix) for topical treatment of inflammatory lesions of non-nodular moderate to severe acne in patients ≥9 years old. It is the first topical tetracycline formulation to be approved for use in patients with acne. Oral minocycline (Minocin, Solodyn, and generics) is
Med Lett Drugs Ther. 2020 May 4;62(1597):68-70 |  Show IntroductionHide Introduction

Eptinezumab (Vyepti) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
. Neurology 2019; 92 (15 Suppl). 86 The Medical Letter ® Vol. 62 (1599) June 1, 2020 headaches in adults ...
The FDA has approved eptinezumab-jjmr (Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth monoclonal antibody to be approved for this indication; erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), which are all given subcutaneously once monthly (fremanezumab can also be given once every 3 months), were approved earlier.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):85-7 |  Show IntroductionHide Introduction

Viloxazine ER (Qelbree) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
Letter ® Vol. 63 (1627) June 28, 2021 PREGNANCY AND LACTATION — Viloxazine was associated with fetal ...
The FDA has approved viloxazine extended-release capsules (Qelbree – Supernus) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. Viloxazine is the second selective norepinephrine reuptake inhibitor to be approved in the US for treatment of ADHD; atomoxetine (Strattera, and generics) was approved in 2002.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):98-100 |  Show IntroductionHide Introduction

Ponesimod (Ponvory) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
to confirmed disability accumulation at 12 and 24 weeks.8 The Medical Letter ® Vol. 63 (1630) August 9, 2021 ...
The FDA has approved ponesimod (Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod (Zeposia) and siponimod (Mayzent) are also approved for use in adults, and fingolimod (Gilenya) is indicated for use in patients...
Med Lett Drugs Ther. 2021 Aug 9;63(1630):123-5 |  Show IntroductionHide Introduction